Skip to Main Content

Try STAT+ TODAY

biologics

Most Read

First Opinion Sean McGowan

Five years on, biosimilars need support from all health care players

First Opinion Leah Christl

From bench to bedside, biologics require excellence at every stage

First Opinion John E. Osborn

Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward

Business Sharon Begley

STAT Plus: Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

First Opinion Jonathan Kimball

Trade agreement drug monopoly is obsolete given faster, better drug discovery

First Opinion Brad Jordan

U.S. biologics and biosimilars need distinguishable names

First Opinion Carlos Sattler and Sheila Frame

Biosimilar approval and adoption in the U.S. needs to be expedited

Biotech Kate Sheridan

STAT Plus: Microbiome-based drugs likely to face FDA’s biologics pathway

All Coverage

First Opinion William Feehery and Julie Bullock

STAT Plus: Three steps can help companies speed FDA approval of new drugs

First Opinion William S. Smith

STAT Plus: The Biden administration needs to look beyond ICER for evaluating drug therapies

advertisement

Pharmalot Ed Silverman

STAT Plus: Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Biotech Elizabeth Cooney

STAT Plus: Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Politics Nicholas Florko

STAT Plus: Lawmakers slip a win for pharma into federal spending package

Politics Erin Mershon

STAT Plus: Drug makers jostle over potential Medicare changes in congressional spending deal

First Opinion Michelle Hoffmann

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

Business Associated Press

Samsung’s biotech unit debuts in Seoul. Here’s what to know

In the Lab Eric Boodman

Freeze-dried drug factories could make a slew of medicines — just add water

Pharmalot Ed Silverman

Biosimilar names may affect pharmacist dispensing habits

Pharmalot Ed Silverman

Some biosimilars are just as good as some pricey biologics

Pharmalot Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Pharmalot Ed Silverman

STAT Plus: Court ruling on biosimilar launches could increase health care costs

Pharmalot Ed Silverman

Bill introduced to speed cheaper versions of pricey biologics to market

Pharmalot Ed Silverman

Supreme Court asks Obama administration for views on biosimilar rules

Pharmalot Ed Silverman

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

Pharmalot Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers